DOCSLIB.ORG

(Insulin Plus Oral Medication) in Type 2 Diabetes?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(Insulin Plus Oral Medication) in Type 2 Diabetes? JFP_1106_CIs.Final 10/17/06 1:51 PM Page 1001 From the CLINICAL INQUIRIES Family Physicians Inquiries Network Staci Eskesen, MD, Gary Kelsberg, MD What is the role of combination Valley Family Medicine therapy (insulin plus oral Residency, Renton, Wash Kristin Hitchcock, MSI Department of Family medication) in type 2 diabetes? Medicine, University of Chicago EVIDENCE- BASED ANSWER Combination therapy using insulin plus met- lurea, but results in more weight gain (SOR: formin (Glucophage), a sulfonylurea, or both A, based on RCT). Using insulin glargine produces glycemic control comparable with (Lantus) in combination therapy produces using insulin alone, but there is less weight ®fewerDowden nocturnal hypoglycemic Health eventsMedia than gain when metformin is used (strength of using neutral protamine Hagedorn (NPH) recommendation [SOR]: B, based on insulin, while producing equivalent HbA1c systematic review of randomizedCopyright controlledFor reductionpersonal (SOR: Buse, based only on RCT). trials [RCTs] with some heterogeneity). When the HbA1c is high (above 9.0% to Combination therapy using insulin and 9.5%) on 1 or 2 oral agents, beginning pioglitazone (Actos) reduces glycosylated combination therapy is more effective than hemoglobin (HbA1c) more than either insulin adding another oral agent (SOR: B, based alone or adding pioglitazone to a sulfony- on subpopulation analysis in RCTs). CLINICAL COMMENTARY Educate patients from the time patient compliance. It is little wonder that of diagnosis that insulin is not a failure many patients perceive a physician’s eventu- Combination therapy for patients with type 2 al recommendation for insulin therapy as a diabetes is a safe and effective stepping personal failure. Patients are also concerned stone between oral therapy and insulin ther- about the discomfort, inconvenience, and apy. Unfortunately, significant barriers remain risk of insulin injections. Physicians should to getting insulin started when oral agents focus on educating their patients from the alone are insufficient. Patients often do not time of diagnosis that insulin is not a failure, understand the common need for insulin but just another tool that will help them therapy as type 2 diabetes advances, and achieve their blood sugar goals. some physicians continue to use the threat Vincent Lo, MD of insulin as a punitive incentive to promote San Joaquin General Hospital, French Camp, Calif ❚ Evidence summary ing to insulin alone in patients with type A systematic review evaluated beginning 2 diabetes mellitus with inadequate combination therapy (adding insulin to glycemic control on oral medication.1 oral medication) compared with switch- Twenty RCTs studied a total of 1811 www.jfponline.com VOL 55, NO 11 / NOVEMBER 2006 1001 For mass reproduction, content licensing and permissions contact Dowden Health Media. JFP_1106_CIs.Final 10/17/06 1:51 PM Page 1002 INQUIRIES patients; glycemic control was the pri- An open-label RCT with 341 patients mary outcome measure. Oral medication who were inadequately controlled on comprised either sulfonylureas (75%), metformin compared beginning combina- metformin (4%), or both (21%). tion therapy (biphasic insulin aspart CLINICAL Individual studies used different insulin 30/70 [Novolog Mix 70/30] and met- dosing schedules and statistical measures. formin) with switching to insulin alone However, overall, combination therapy (biphasic insulin aspart 30/70).5 A third provided glucose control comparable group added a second oral medication with insulin alone. In only 1 small, low- (sulfonylurea and metformin). After 16 quality study did insulin plus metformin weeks, patients taking combination ther- reduce HbA1c more than other combina- apy had a significantly lower HbA1c than tion therapy regimens or insulin alone. those on insulin alone (treatment differ- Ten studies reported a trend toward less ence 0.39%, P=.007). weight gain with combination therapy Overall, combination therapy and 2 that included metformin. Fourteen studies oral medications reduced HbA1c by the found the same incidence of hypo- same amount, but combination therapy glycemic episodes in combination therapy reduced HbA1c more in a subpopulation and insulin alone. of patients with HbA1c >9.0% at baseline Three later RCTs of overweight (treatment difference 0.46%, P=.027). patients with inadequate control on oral The group on insulin alone weighed sig- agents (HbA1c >7% on a sulfonylurea, nificantly more (4.6 kg, P<.001) at the metformin, or both) also compared end of the trial than the group taking 2 beginning combination therapy with oral medications. switching to insulin alone (with 70/30 or An open-label RCT of 756 patients NPH insulin twice daily). In one study with inadequate glycemic control (HbA1c with 64 patients followed for 12 months, >7.5%, mean 8.6%) on either 1 or 2 oral HbA1c fell by 0.14% less (nonsignificant) agents (70% taking both metformin and in the combination therapy group (bed- a sulfonylurea) compared combination FAST TRACK time NPH plus sulfonylurea and met- therapy using bedtime insulin glargine When HbA is formin) than in the insulin alone group with combination therapy using morning 1c (70/30 twice daily).2 The combination NPH.6 Each group titrated insulin doses high, beginning therapy group gained significantly less to achieve a target fasting glucose ≤100. combination weight than the insulin-alone group (1.3 By 24 weeks, both groups had equivalent- therapy is more kg vs 4.2 kg; P=.01). ly reduced HbA1c (mean HbA1c=6.96% In the second study of 261 patients, with glargine, and 6.97% with NPH; effective than the combination therapy group P=NS), but fewer patients experienced adding another (glimepiride [Amaryl] plus bedtime NPH) nocturnal hypoglycemia with glargine oral agent had a significantly higher HbA1c after 9 than with NPH (33.2% vs 26.7%, months than 2 groups using insulin alone P<.05). (twice daily 70/30, and twice daily NPH Another open-label RCT evaluated insulin) (8.9% vs 8.3% and 8.4%).3 281 patients with at least 3 months of Mean weight gain was similar in all 3 inadequate glycemic control (HbA1c= groups but only a minority of patients 7.4%–14.7%) on a sulfonylurea.7 reached a target HbA1c of 6.5%. In the Patients were randomized to a) switching final study of only 16 patients, HbA1c to a combination of biphasic insulin after 6 months improved significantly and aspart 30/70 plus pioglitazone, b) adding equally in both groups (baseline: 8.3%, pioglitazone to the sulfonylurea, or c) combination therapy final: 6.8%; insulin switching to insulin alone (biphasic alone final: 7.0%). However, the combi- insulin aspart 30/70). After 18 weeks, nation therapy group gained significantly insulin plus pioglitazone reduced HbA1c less weight.4 significantly more than either glyburide 1002 VOL 55, NO 11 / NOVEMBER 2006 THE JOURNAL OF FAMILY PRACTICE JFP_1106_CIs.Final 10/17/06 1:51 PM Page 1003 Combination therapy in type 2 diabetes ▲ plus pioglitazone (P=.005) or insulin trial . Diabetes Metab Res Rev 2003; 19:148-152. 4. Olsson PO, Lindstrom T. Combination-therapy with bed- alone (P=.005). However, the insulin plus time NPH insulin and sulphonylureas gives similar gly- caemic control but lower weight gain than insulin twice pioglitazone group had the most weight daily in patients with type 2 diabetes. Diabetes Metab gain (mean 4 kg, similar to other pioglita- 2002; 28(4 Pt 1):272-277. zone trials). There were no major hypo- 5. Kvapil M, Swatko A, Hilberg C, Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination glycemic events. in type 2 diabetes. Diabetes Obes Metab 2006; 8:39-48. Another open-label RCT evaluated 7. Riddle MC, Rosenstock J, Gerich J, and the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: 217 patients inadequately controlled randomized addition of glargine or human NPH insulin to (HbA1c=7.5%–11%) on a 2-drug oral oral therapy of type 2 diabetic patients. Diabetes Care regimen (metformin and a sulfonylurea, 2003; 26:3080-3086. 7. Raz I, Stranks S, Filipczak R, et al. Efficacy and safety of each drug dosed at ≥50% of the recom- biphasic insulin aspart 30 combined with pioglitazone in mended maximum), randomized to add type 2 diabetes poorly controlled on glibenclamide (gly- buride) monotherapy or combination therapy: an 18 week, either insulin glargine or rosiglitazone randomized, open-label study. Clin Ther 2005; 27:1432- 8 1443. (Avandia). Both groups reduced HbA1c 8. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes- equivalently after 24 weeks (–1.7% for Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine vs –1.5% for rosiglitazone). glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. However, in patients with a baseline Diabetes Care 2006; 29:554-559. HbA1c >9.5%, adding insulin glargine 9. Burgers JS, Grol R, Klazinga NS, et al. Inside guidelines: comparative analysis of recommendations and evidence in reduced HbA1c significantly more than diabetes guidelines from 13 countries. Diabetes Care 2002; rosiglitazone. 25:1933-1939. 10. European Diabetes Policy Group 1999. A desktop guide to Type 2 diabetes mellitus. Diabet Med 1999; 16:716-730. Recommendations by others A comparative analysis of guidelines on diabetes from 13 different countries (including the US) found general agree- ment in the recommendation to add a sec- ond oral agent to maximum doses of an initial agent in patients with poor glycemic control.9 However, no consensus FAST TRACK was reached on the value or indications of Ten studies combination therapy with oral agents and insulin. reported a trend The European Diabetes Policy Group toward less recommends adding a second oral agent weight gain when the maximum dose of a single agent is reached, and using triple therapy with combination when targets are not reached on maxi- therapy that mum tolerated doses of 2 agents. included metformin Continued therapy with oral agents is advised when initiating insulin.10 REFERENCES 1.
Load more

Recommended publications
  • Insulin Aspart Sanofi, If It Is Coloured Or It Has Solid Pieces in It
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Insulin aspart Sanofi 100 units/ml solution for injection in vial Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg). Insulin aspart Sanofi 100 units/ml solution for injection in vial Each vial contains 10 ml equivalent to 1,000 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Each cartridge contains 3 ml equivalent to 300 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen Each pre-filled pen contains 3 ml equivalent to 300 units insulin aspart. Each pre-filled pen delivers 1-80 units in steps of 1 unit. *produced in Escherichia coli by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. 4.2 Posology and method of administration Posology The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
    [Show full text]
  • Comparative Transcriptional Network Modeling of Three PPAR-A/C Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes
    Comparative Transcriptional Network Modeling of Three PPAR-a/c Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes Rene´e Deehan1, Pia Maerz-Weiss2, Natalie L. Catlett1, Guido Steiner2, Ben Wong1, Matthew B. Wright2*, Gil Blander1¤a, Keith O. Elliston1¤b, William Ladd1, Maria Bobadilla2, Jacques Mizrahi2, Carolina Haefliger2, Alan Edgar{2 1 Selventa, Cambridge, Massachusetts, United States of America, 2 F. Hoffmann-La Roche AG, Basel, Switzerland Abstract Aims: To compare the molecular and biologic signatures of a balanced dual peroxisome proliferator-activated receptor (PPAR)-a/c agonist, aleglitazar, with tesaglitazar (a dual PPAR-a/c agonist) or a combination of pioglitazone (Pio; PPAR-c agonist) and fenofibrate (Feno; PPAR-a agonist) in human hepatocytes. Methods and Results: Gene expression microarray profiles were obtained from primary human hepatocytes treated with EC50-aligned low, medium and high concentrations of the three treatments. A systems biology approach, Causal Network Modeling, was used to model the data to infer upstream molecular mechanisms that may explain the observed changes in gene expression. Aleglitazar, tesaglitazar and Pio/Feno each induced unique transcriptional signatures, despite comparable core PPAR signaling. Although all treatments inferred qualitatively similar PPAR-a signaling, aleglitazar was inferred to have greater effects on high- and low-density lipoprotein cholesterol levels than tesaglitazar and Pio/Feno, due to a greater number of gene expression changes in pathways related to high-density and low-density lipoprotein metabolism. Distinct transcriptional and biologic signatures were also inferred for stress responses, which appeared to be less affected by aleglitazar than the comparators. In particular, Pio/Feno was inferred to increase NFE2L2 activity, a key component of the stress response pathway, while aleglitazar had no significant effect.
    [Show full text]
  • Lobeglitazone
    2013 International Conference on Diabetes and Metabolism Lobeglitazone, A Novel PPAR-γ agonist with balanced efficacy and safety Kim, Sin Gon. MD, PhD. Professor, Division of Endocrinology and Metabolism Department of Internal Medicine, Korea University College of Medicine. Disclosure of Financial Relationships This symposium is sponsored by Chong Kun Dang Pharmaceutical Corp. I have received lecture and consultation fees from Chong Kun Dang. Pros & Cons of PPAR-γ agonist Pros Cons • Good glucose lowering • Adverse effects • Durability (ADOPT) (edema, weight gain, • Insulin sensitizing CHF, fracture or rare effects (especially in MS, macular edema etc) NAFLD, PCOS etc) • Possible safety issues • Prevention of new- (risk of MI? – Rosi or onset diabetes (DREAM, bladder cancer? - Pio) ACT-NOW) • LessSo, hypoglycemiathere is a need to develop PPAR-γ • Few GI troubles agonist• Outcome with data balanced efficacy and safety (PROactive) Insulin Sensitizers : Several Issues Rosi, Peak sale ($3.3 billion) DREAM Dr. Nissen Dr. Nissen ADOPT META analysis BARI-2D (5,8) Rosi, lipid profiles RECORD 1994 1997 1999 2000 2002 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Tro out d/t FDA, All diabetes hepatotoxicity drug CV safety Rosi (5) FDA, Black box Rosi, Rosi , CV safety warning - REMS in USA = no evidence - Europe out Pio (7) PIO, bladder cancer CKD 501 Lobeglitazone 2000.6-2004.6 2004.11-2007.1 2007.3-2008.10 2009.11-2011.04 Discovery& Preclinical study Phase I Phase II Phase III Developmental Strategy Efficacy • PPAR activity Discovery & Preclinical study • In vitro & vivo efficacy • Potent efficacy 2000.06 - 2004.06 Phase I 2004.11 - 2007.01 • In vitro screening • Repeated dose toxicity • Metabolites • Geno toxicity • Phase II CYP 450 • Reproductive toxicity 2007.03 - 2008.10 • DDI • Carcinogenic toxicity ADME Phase III Safety 2009.11 - 2011.04 CV Safety / (Bladder) Cancer / Liver Toxicity / Bone loss Lobeglitazone (Duvie) 1.
    [Show full text]
  • Title: Combination of Pparg Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas
    Author Manuscript Published OnlineFirst on September 3, 2019; DOI: 10.1158/1078-0432.CCR-19-0976 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Title: Combination of PPARg agonist pioglitazone and trabectedin induce adipocyte differentiation to overcome trabectedin resistance in myxoid liposarcomas Roberta Frapolli1, Ezia Bello1, Marianna Ponzo1, Ilaria Craparotta2, Laura Mannarino2, Sara Ballabio2, Sergio Marchini2, Laura Carrassa3, Paolo Ubezio4, Luca Porcu5, Silvia Brich6, Roberta Sanfilippo7, Paolo Giovanni Casali7, Alessandro Gronchi8, Silvana Pilotti6, and Maurizio D’Incalci9*. 1 Unit of Preclinical Experimental Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 2 Unit of Translational Genomic, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 3Unit of DNA repair, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 4 Unit of Biophysics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 5 Unit of Methodological Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 6Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. 7 Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. 8 Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. 9 Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. Running title: Pioglitazone - trabectedin in myxoid liposarcomas. Keywords: Myxoid liposarcoma, trabectedin resistance, PPAR agonist, and patient-derived xenograft. Additional information: Financial support: This work was supported by the Italian Association for Cancer Research grant to M.D.
    [Show full text]
  • OSENI Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------WARNINGS AND PRECAUTIONS---------------------- These highlights do not include all the information needed to use Congestive heart failure: Fluid retention may occur and can OSENI safely and effectively. See full prescribing information for exacerbate or lead to congestive heart failure. Combination use OSENI. with insulin and use in congestive heart failure NYHA Class I and OSENI (alogliptin and pioglitazone) tablets II may increase risk. Monitor patients for signs and symptoms. Initial U.S. Approval: 2013 (5.1) Acute pancreatitis: There have been postmarketing reports of WARNING: CONGESTIVE HEART FAILURE acute pancreatitis. If pancreatitis is suspected, promptly See full prescribing information for complete boxed warning discontinue OSENI. (5.2) Thiazolidinediones, including pioglitazone, cause or Hypersensitivity: There have been postmarketing reports of exacerbate congestive heart failure in some patients. (5.1) serious hypersensitivity reactions in patients treated with alogliptin After initiation of OSENI and after dose increases, monitor such as anaphylaxis, angioedema and severe cutaneous adverse patients carefully for signs and symptoms of heart failure reactions. In such cases, promptly discontinue OSENI, assess for (e.g., excessive, rapid weight gain, dyspnea, and/or other potential causes, institute appropriate monitoring and edema). If heart failure develops, it should be managed treatment, and initiate alternative treatment for diabetes. (5.3) according to current standards of care and Hepatic effects: Postmarketing reports of hepatic failure, discontinuation or dose reduction of pioglitazone in OSENI sometimes fatal. Causality cannot be excluded. If liver injury is must be considered. detected, promptly interrupt OSENI and assess patient for OSENI is not recommended in patients with symptomatic probable cause, then treat cause if possible, to resolution or heart failure.
    [Show full text]
  • Muraglitazar Bristol-Myers Squibb/Merck Daniella Barlocco
    Muraglitazar Bristol-Myers Squibb/Merck Daniella Barlocco Address Originator Bristol-Myers Squibb Co University of Milan . Istituto di Chimica Farmaceutica e Tossicologica Viale Abruzzi 42 Licensee Merck & Co Inc 20131 Milano . Italy Status Pre-registration Email: [email protected] . Indications Metabolic disorder, Non-insulin-dependent Current Opinion in Investigational Drugs 2005 6(4): diabetes © The Thomson Corporation ISSN 1472-4472 . Actions Antihyperlipidemic agent, Hypoglycemic agent, Bristol-Myers Squibb and Merck & Co are co-developing Insulin sensitizer, PPARα agonist, PPARγ agonist muraglitazar, a dual peroxisome proliferator-activated receptor-α/γ . agonist, for the potential treatment of type 2 diabetes and other Synonym BMS-298585 metabolic disorders. In November 2004, approval was anticipated as early as mid-2005. Registry No: 331741-94-7 Introduction [579218], [579221], [579457], [579459]. PPARγ is expressed in Type 2 diabetes is a complex metabolic disorder that is adipose tissue, lower intestine and cells involved in characterized by hyperglycemia, insulin resistance and immunity. Activation of PPARγ regulates glucose and lipid defects in insulin secretion. The disease is associated with homeostasis, and triggers insulin sensitization [579216], older age, obesity, a family history of diabetes and physical [579218], [579458], [579461]. PPARδ is expressed inactivity. The prevalence of type 2 diabetes is increasing ubiquitously and has been found to be effective in rapidly, and the World Health Organization warns that, controlling dyslipidemia and cardiovascular diseases unless appropriate action is taken, the number of sufferers [579216]. PPARα agonists are used as potent hypolipidemic will double to over 350 million individuals by the year compounds, increasing plasma high-density lipoprotein 2030. Worryingly, it is estimated that only half of sufferers (HDL)-cholesterol and reducing free fatty acids, are diagnosed with the condition [www.who.int].
    [Show full text]
  • Structural Basis for the Enhanced Anti-Diabetic Efficacy Of
    www.nature.com/scientificreports OPEN Structural Basis for the Enhanced Anti-Diabetic Efcacy of Lobeglitazone on PPARγ Received: 9 October 2017 Jun Young Jang 1, Hwan Bae2, Yong Jae Lee3, Young Il Choi3, Hyun-Jung Kim4, Accepted: 4 December 2017 Seung Bum Park 2, Se Won Suh2, Sang Wan Kim 5 & Byung Woo Han 1 Published: xx xx xxxx Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear receptor superfamily. It functions as a ligand-activated transcription factor and plays important roles in the regulation of adipocyte diferentiation, insulin resistance, and infammation. Here, we report the crystal structures of PPARγ in complex with lobeglitazone, a novel PPARγ agonist, and with rosiglitazone for comparison. The thiazolidinedione (TZD) moiety of lobeglitazone occupies the canonical ligand-binding pocket near the activation function-2 (AF-2) helix (i.e., helix H12) in ligand-binding domain as the TZD moiety of rosiglitazone does. However, the elongated p-methoxyphenol moiety of lobeglitazone interacts with the hydrophobic pocket near the alternate binding site of PPARγ. The extended interaction of lobeglitazone with the hydrophobic pocket enhances its binding afnity and could afect the cyclin- dependent kinase 5 (Cdk5)-mediated phosphorylation of PPARγ at Ser245 (in PPARγ1 numbering; Ser273 in PPARγ2 numbering). Lobeglitazone inhibited the phosphorylation of PPARγ at Ser245 in a dose-dependent manner and exhibited a better inhibitory efect on Ser245 phosphorylation than rosiglitazone did. Our study provides new structural insights into the PPARγ regulation by TZD drugs and could be useful for the discovery of new PPARγ ligands as an anti-diabetic drug, minimizing known side efects.
    [Show full text]
  • Thiazolidinedione Drugs Down-Regulate CXCR4 Expression on Human Colorectal Cancer Cells in a Peroxisome Proliferator Activated Receptor Á-Dependent Manner
    1215-1222 26/3/07 18:16 Page 1215 INTERNATIONAL JOURNAL OF ONCOLOGY 30: 1215-1222, 2007 Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor Á-dependent manner CYNTHIA LEE RICHARD and JONATHAN BLAY Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, B3H 1X5, Canada Received October 26, 2006; Accepted December 4, 2006 Abstract. Peroxisome proliferator activated receptor (PPAR) Introduction Á is a nuclear receptor involved primarily in lipid and glucose metabolism. PPARÁ is also expressed in several cancer types, Peroxisome proliferator activated receptors (PPARs) are and has been suggested to play a role in tumor progression. nuclear hormone receptors that are involved primarily in PPARÁ agonists have been shown to reduce the growth of lipid and glucose metabolism (1). Upon ligand activation, colorectal carcinoma cells in culture and in xenograft models. these receptors interact with the retinoid X receptor (RXR) Furthermore, the PPARÁ agonist thiazolidinedione has been and bind to peroxisome proliferator response elements (PPREs), shown to reduce metastasis in a murine model of rectal cancer. leading to transcriptional regulation of target genes. Members Since the chemokine receptor CXCR4 has emerged as an of the thiazolidinedione class of antidiabetic drugs act as important player in tumorigenesis, particularly in the process ligands for PPARÁ (2), as does endogenously produced 15- 12,14 of metastasis, we sought to determine if PPARÁ agonists deoxy-¢ -prostaglandin J2 (15dPGJ2) (3). might act in part by reducing CXCR4 expression. We found In addition to regulation of glucose metabolism, PPARÁ that rosiglitazone, a thiazolidinedione PPARÁ agonist used appears also to be involved in tumorigenesis, although its primarily in the treatment of type 2 diabetes, significantly exact role has yet to be elucidated (4).
    [Show full text]
  • Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
    ORIGINAL ARTICLE Endocrinology, Nutrition & Metabolism https://doi.org/10.3346/jkms.2017.32.1.60 • J Korean Med Sci 2017; 32: 60-69 Lobeglitazone, a Novel Thiazolidinedione, Improves Non- Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness Yong-ho Lee,1* Jae Hyeon Kim,2* Despite the rapidly increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in So Ra Kim,1 Heung Yong Jin,3 type 2 diabetes (T2D), few treatment modalities are currently available. We investigated Eun-Jung Rhee,4 Young Min Cho,5 the hepatic effects of the novel thiazolidinedione (TZDs), lobeglitazone (Duvie) in T2D and Byung-Wan Lee1 patients with NAFLD. We recruited drug-naïve or metformin-treated T2D patients with NAFLD to conduct a multicenter, prospective, open-label, exploratory clinical trial. 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; 2Division of Transient liver elastography (Fibroscan®; Echosens, Paris, France) with controlled Endocrinology and Metabolism, Department of attenuation parameter (CAP) was used to non-invasively quantify hepatic fat contents. Medicine, Samsung Medical Center, Sungkyunkwan Fifty patients with CAP values above 250 dB/m were treated once daily with 0.5 mg University School of Medicine, Seoul, Korea; lobeglitazone for 24 weeks. The primary endpoint was a decline in CAP values, and 3Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute secondary endpoints included changes in components of glycemic, lipid, and liver profiles. of Clinical Medicine, Chonbuk National University Lobeglitazone-treated patients showed significantly decreased CAP values (313.4 dB/m at Hospital, Chonbuk National University Medical baseline vs.
    [Show full text]
  • Pioglitazone (Actos®)
    VERDICT & SUMMARY Pioglitazone (Actos®) For the treatment of type 2 diabetes mellitus Committee’s Verdict: Category B (Q4) BNF: 6.1.2 Pioglitazone is suitable for use in primary care by a prescriber with a particular interest in type 2 diabetes who can identify patients likely to benefit from treatment, and monitor for side effects, e.g. heart failure. There is conflicting evidence whether pioglitazone is associated with long-term clinical benefits or harms on cardiovascular outcomes, which dictates caution in its use. Category B: suitable for restricted prescribing under defined conditions Q4 rating: One RCT and two meta-analyses evaluated the effect of pioglitazone treatment on cardiovascular mortality and morbidity compared Q2 Q1 higher place higher place with control treatment. All three studies found a higher risk of heart failure weaker evidence stronger evidence with pioglitazone, but the results were conflicting for other cardiovascular outcomes. Pioglitazone has been found to improve glycaemic control compared with placebo, as monotherapy or in combination with other Q4 Q3 antidiabetic agents, but it was not superior to other agents. Therefore, it is lower place lower place considered to have a relatively low place in therapy. weaker evidence stronger evidence The Q rating relates to the drug’s position on the effectiveness indicator grid. in primary carePlace therapy in The strength of the evidence is determined by the quality and quantity of studies Strength of evidence for efficacy that show significant efficacy of the drug compared with placebo or alternative therapy. Its place in therapy in primary care takes into account safety and practical aspects of using the drug in primary care, alternative options, relevant NICE guidance, and the need for secondary care input.
    [Show full text]
  • Insulin Aspart Mix PI
    Insulin Aspart Protamine and Insulin Aspart Injectable Suspension Mix 70/30 HIGHLIGHTS OF PRESCRIBING INFORMATION • Insulin Aspart Protamine and Insulin Aspart Injectable Discontinue Insulin Aspart Protamine and Insulin Aspart These highlights do not include all the information Suspension Mix 70/30 is typically dosed twice-daily (with Injectable Suspension Mix 70/30, treat, and monitor, if needed to use Insulin Aspart Protamine and Insulin each dose intended to cover 2 meals or a meal and a snack) indicated (5.5). Aspart Injectable Suspension Mix 70/30 safely and (2.2). • Hypokalemia: May be life-threatening. Monitor potassium effectively. See full prescribing information for • Individualize dosage based on metabolic needs, blood levels in patients at risk of hypokalemia and treat if indicated Insulin Aspart Protamine and Insulin Aspart Injectable glucose monitoring results, glycemic control goal (2.2). (5.6). Suspension Mix 70/30. • Dosage adjustments may be needed with changes in physical • Fluid retention and heart failure with concomitant use of Insulin Aspart Protamine and Insulin Aspart Injectable activity, changes in meal patterns (i.e., macronutrient content thiazolidinediones (TZDs): Observe for signs and symptoms Suspension Mix 70/30, for subcutaneous use or timing of food intake), changes in renal or hepatic function of heart failure; consider dosage reduction or discontinuation Initial U.S. Approval: 2001 or during acute illness (2.2). if heart failure occurs (5.7). • Dosage adjustment may be needed when switching from ——— ADVERSE REACTIONS ——— ——— RECENT MAJOR CHANGES ——— another insulin to Insulin Aspart Protamine and Insulin Dosage and Administration (2.1) ----------------------- 11/2019 Aspart Injectable Suspension Mix 70/30 (2.2).
    [Show full text]
  • Effects of Pioglitazone and Rosiglitazone on Blood Lipid
    CLINICAL THERAPEUTICSVVOL.24, NO. 3,2002 Effects of Pioglitazone and Rosiglitazone on Blood Lipid Levels and Glycemic Control in Patients with Qpe 2 Diabetes Mellitus: A Retrospective Review of Randomly Selected Medical Records Patrick J. Boyle, MD,’ Allen Bennett King, MD,2 Leann Ohmsky, MD,3 Albert Marchetti, MD,4 Helen Lm, MS,4 Raf Magar, BS,4 and John Martin, MPH4 IDepartment of In ternal Medicine, School of Medicine, University of New Mexico, Albuquerque, New Mexico, 2Department of Family and Community Medicine, School of Medicine, University of California San Francisco, San Francisco, California, 3Section of Endocrinology, Metabolism, and Hypertension, School of Medicine, University of Oklahoma, Oklahoma City, Oklahoma, and 4Health Economics Research, Secaucus, New Jersey ABSTRACT Buckgrolmd: The antihyperglycemic effects of pioglitazone hydrochloride and rosigli- tazone maleate are well documented. The results of clinical trials and observational stud- ies have suggested, however, that there are individual differences in the effects of these drugs on blood lipid levels. Objective: The present study evaluated the effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus. Methods: This was a retrospective review of randomly selected medical records from 605 primary care practices in the United States in which adults with type 2 diabetes re- ceived pioglitazone or rosiglitazone between August 1, 1999, and August 3 1, 2000. The outcome measures were mean changes in serum concentrations of triglycerides (TG), to- tal cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipopro- tein cholesterol (LDL-C), and glycosylated hemoglobin (HbAIJ values. Results: Treatment with pioglitazone was associated with a reduction in mean TG of 55.17 mg/dL, a reduction in TC of 8.45 mg/dL, an increase in HDL-C of 2.65 mg/dL, and a reduction in LDL-C of 5.05 mg/dL.
    [Show full text]